CN Mobile Logo

Search form


Gynecologic Cancers

Gynecologic Cancers

The oral PARP inhibitor rucaparib showed strong activity and an acceptable safety profile in women with high-grade, BRCA-mutated ovarian carcinoma who had previously received at least two lines of chemotherapy.

Microsatellite instability analysis and immunohistochemistry analysis are highly concordant with regard to testing for mismatch repair deficiency in endometrial cancer.

The oral PARP inhibitor niraparib yielded significantly improved progression-free survival for women with platinum-sensitive, recurrent ovarian cancer in a phase III trial.

The combination of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and nedaplatin showed promising activity and was relatively well tolerated in a small phase II trial.

The human papillomavirus (HPV) vaccine reduces the incidence of pre-cancerous cervical intraepithelial neoplasia (CIN), according to a population-based study in New Mexico.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that found that surveillance with CA-125 in ovarian cancer patients led to more use of chemotherapy, decreased quality of life, and no improvement in survival.


Subscribe to Gynecologic Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.